- Home
- HG vs LQDA Comparison
HG vs LQDA Comparison
Compare HG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- LQDA
- Stock Information
- Founded
- HG 2013
- LQDA 2004
- Country
- HG Bermuda
- LQDA United States
- Employees
- HG N/A
- LQDA N/A
- Industry
- HG
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- HG
- LQDA Health Care
- Exchange
- HG Nasdaq
- LQDA Nasdaq
- Market Cap
- HG 2.4B
- LQDA 2.5B
- IPO Year
- HG 2023
- LQDA 2018
- Fundamental
- Price
- HG $23.41
- LQDA $26.20
- Analyst Decision
- HG Buy
- LQDA Strong Buy
- Analyst Count
- HG 7
- LQDA 9
- Target Price
- HG $25.71
- LQDA $32.11
- AVG Volume (30 Days)
- HG 486.2K
- LQDA 2.3M
- Earning Date
- HG 11-05-2025
- LQDA 11-12-2025
- Dividend Yield
- HG N/A
- LQDA N/A
- EPS Growth
- HG N/A
- LQDA N/A
- EPS
- HG 3.61
- LQDA N/A
- Revenue
- HG $2,599,247,000.00
- LQDA $19,322,000.00
- Revenue This Year
- HG $18.17
- LQDA $362.31
- Revenue Next Year
- HG $8.74
- LQDA $418.29
- P/E Ratio
- HG $6.69
- LQDA N/A
- Revenue Growth
- HG 21.31
- LQDA 30.20
- 52 Week Low
- HG $16.80
- LQDA $9.68
- 52 Week High
- HG $24.67
- LQDA $29.94
- Technical
- Relative Strength Index (RSI)
- HG 48.88
- LQDA 52.66
- Support Level
- HG $23.29
- LQDA $25.34
- Resistance Level
- HG $24.48
- LQDA $29.43
- Average True Range (ATR)
- HG 0.55
- LQDA 1.30
- MACD
- HG -0.12
- LQDA -0.61
- Stochastic Oscillator
- HG 11.59
- LQDA 19.24
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.